Accepted refereed manuscript of:

1   The effects of increasing dietary levels of soy protein concentrate (SPC) on the immune

2   responses and disease resistance (furunculosis) of vaccinated and non-vaccinated Atlantic

3   salmon (*Salmo salar* L.) parr

4

5   C. Metochis[1], I. Spanos[1], N. Auchinachie[1], V.O. Crampton[2], J.G. Bell[1], A. Adams[1], K.D.

6   Thompson[3]

7

8   *[1]Institute of Aquaculture, School of Natural Sciences, University of Stirling, Stirling FK9*

9   *4LA, Scotland, UK*

10   *[2] EWOS Innovation, N-4335, Dirdal, Norway*

11   *[3]Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, UK*

12

13   **Corresponding author:** Christoforos P. Metochis, Institute of Aquaculture, University of

14   Stirling, Stirling FK9 4LA, UK. Tel: (+44) 1786 466597; Email: c.p.metochis@stir.ac.uk ,

15   xristoforosmetoxis@gmail.com

16   ***Abbreviations***

17   AC, alternative complement; ANF, anti-nutrient factors; BSA, bovine serum albumin; CCP,

18   classical complement pathway; dpv, days post vaccination; EAAs, essential amino acids;

19   ELISA, enzyme linked immunosorbent assay; FM, fishmeal; G-CFB, gelatine-complement

20   fixation buffer; HKM, head kidney macrophages; HSWB, high salt wash buffer; i.p.,

21   intraperitoneal; LRT, likelihood ratio test; LSWB, low salt wash buffer; PBS, phosphate buffer

22   saline; SRBC, sheep red blood cells; SBM, soybean meal; SPC, soy protein concentrate; TSA,

23   tryptic soy agar; TC, total complement.

24

25   ***Keywords: Atlantic salmon, parr, soy protein concentrate, vaccination, immune function***

26 **Abstract**

27 Juvenile salmon, with an initial weight of 9g, were fed three experimental diets, formulated to

28 replace 35 (SPC35), 58 (SPC58) and 80 (SPC80) of high quality fishmeal (FM) with soy

29 protein concentrate (SPC) in quadruplicate tanks. Higher dietary SPC inclusion was combined

30 with increased supplementation of methionine, lysine, L-threonine and phosphorus. The

31 experiment was carried out for 177 days. On day 92 salmon in each tank were bulk weighed.

32 Post weighing eighty salmon from each tank were redistributed in two sets of 12 tanks. Salmon

33 from the first set of tanks were vaccinated, while the second group was injected with phosphate

34 buffer saline (PBS). Salmon were sampled on day 92 (pre-vaccination), day 94 (2 days post

35 vaccination [dpv]/PBS injection [dpPBSinj]) and day 154 (62 dpv/dpPBSinj) of the trial for

36 the assessment of their immune responses, prior to the performance of salmon bulk weights for

37 each tank. On day 154, fish from each tank were again bulk weighed and then seventeen salmon

38 per tank were redistributed in two sets of twelve tanks and intra-peritoneally infected with

39 *Aeromonas salmonicida*. At Day 154, SPC80 demonstrated lower performance (weight gain,

40 specific growth rate and thermal growth coefficient and feed conversion ratio) compared to

41 SPC35 salmon. Reduced classical and total complement activities for salmon fed diets with

42 over 58 % of protein from SPC, were demonstrated prior to vaccination. Reduced alternative

43 complement activity was detected for both SPC58 and SPC80 salmon at 2 dpv and for the

44 SPC80 group at 62 dpv. Total and classical complement activities demonstrated no differences

45 among the dietary groups after vaccination. Numerical increases in classical complement

46 activity were apparent upon increased dietary SPC levels. Increased phagocytic activity (%

47 phagocytosis and phagocytic index) was exhibited for the SPC58 group compared to SPC35

48 salmon at 62 dpPBSinj. No differences in serum lysozyme activity, total IgM, specific

49 antibodies, protein, glucose and HKM respiratory burst were detected among the dietary groups

50 at any timepoint or state. Mortalities as a result of the experimental infection only occurred in

51   PBS-injected fish. No differences in mortality levels were demonstrated among the dietary

52   groups. SPC58 diet supported both good growth and health in juvenile Atlantic salmon while

53   SPC80 diet did not compromise salmon' immunity or resistance to intraperitoneally inflicted

54   furunculosis.

55   **1. Introduction**

56   Farmed Atlantic salmon are typically raised in intensive aquaculture production systems and

57   fed nutritionally complete formulated diets. Historically, fish meal (FM) has been the source

58   of protein and essential amino acids for salmon feeds [1]. In 2009, aquaculture' use of global

59   FM production was estimated to be 68%, with salmonid aquafeeds consuming 13.7% [2].

60   Unless alternative protein sources are used, the reliance of salmon diets on FM may reduce the

61   potential for salmon culture growth, since the worldwide demand for FM is rapidly exceeding

62   supply. Given that plant feedstuffs are readily available, these have received most attention as

63   an alternative to FM [3-6].

64   Among plant protein ingredients, SPC manufactured through aqueous alcohol extraction

65   of defatted soybeans is a very promising protein source for Atlantic salmon. Alcohol extracted

66   SPC has a protein content, which is very similar to that of FM [7], while its EAA content

67   compares favourably with FM, with the exception of methionine and potentially lysine [8].

68   Furthermore, lectins, saponins soy antigens and trypsin inhibitors concentrations, which are

69   ANFs, are found at lower the concentrations than those found in conventional SBM [9-11].

70   Several studies have demonstrated the suitability of SPC as an alternative to FM in Atlantic

71   salmon post smolt diets [12-14]. Moreover, a few studies reported the absence of soybean-

72   induced intestinal inflammation in salmonids receiving diets with even 100% substitution of

73   FM with SPC [15-16]. However, the tolerance of salmon for plant feedstuffs depends on

74   salmon size and stage. Burr et al. [17] demonstrated that early stage Atlantic salmon parr are

75   much more sensitive to dietary vegetal protein inclusion than late stage Atlantic salmon parr.

76   Previous studies exploring the effects of increasing dietary levels of plant derived

77   ingredients on the immunity of several fish species have reported adverse effects of diets with

78   over 70% of dietary protein from plant derived feedstuffs on immune responses such as the

79   total serum immunoglobulin levels and alternative complement activity in rainbow trout

80   *Oncorhynchus mykiss* [18] and the alternative complement activity of gilthead sea bream

81   *Sparus aurata* [19]. While studies on the use of soybean meals in salmonid diets and their

82   subsequent effects on immune function have been undertaken, only few have investigated the

83   effects of dietary SPC on Atlantic salmon immune responses [1, 16, 20-21]. Briefly, Krogdahl

84   et al. [16] demonstrated an enhancement of lysozyme activity and total IgM levels in the

85   intestinal mucosa of Atlantic salmon smolts, maintained on feeds with 30% of dietary protein

86   from soy products (SBM and SPC), and in turn, enhanced resistance of SPC fed salmon to

87   infection by *A. salmonicida* the causative agent of furunculosis. Moreover, Metochis et al. [21]

88   reported no adverse effects in the immune responses of large size Atlantic salmon parr

89   commercially reared under constant light and intensive feeding with amino acid supplemented

90   diets formulated with up to 80% of protein SPC and constant supplementation of phosphorus

91   compared to a commercial type diet with up to 35% of protein from SPC.

92   Furunculosis is a highly infectious disease, causing serious fish losses, such as those

93   observed during the epidemic of 1991-1992, which led to the loss of approximately 25% of the

94   total Scottish salmon production [22]. Successful vaccination has enabled the disease to be

95   brought under control and currently the majority of farmed Scottish and Norwegian Atlantic

96   salmon are vaccinated against fununculosis. Thus, vaccination with a commercial *A.*

97   *salmonicida* vaccine and subsequent infection challenge of the experimental Atlantic salmon

98   parr in this study was used to describe the effects of increasing dietary SPC levels on immune

99   responses upon vaccination and the resistance of Atlantic salmon parr against furunculosis.

100   Since the site(s) of pathogen uptake into fish, is a subject of conjecture and seems likely to

101   include gills, mouth, anus and/or surface injury [23-26] an i.p. injection of *A. salmonicida* was

102   used for the infection of Atlantic salmon parr in this study.

103   Generally, soy products and several other vegetable derived products used as FM

104   replacements have been shown to affect a range of immune responses in fishes and these have

105   been interpreted as inflammatory/hypersensitivity or immunostimulatory effects [16, 19-22].

106   In spite of the fact that commercial application of aquafeeds with higher than 58% of dietary

107   protein from SPC is unlikely, due to the high cost of this feedstuff in comparison to other FM

108   alternatives, the above diets were tested in this framework in order to augment dietary

109   responses, highlighting nutritional deficiencies. Herein, the main objective was to monitor how

110   increased dietary SPC, methionine, lysine and phosphate inclusion (to give similar amino

111   acid/protein ratios and increase the availability of P in diets with higher levels of SPC) affects

112   the immunological responses of naïve and vaccinated (against *A. salmonicida)* Atlantic salmon

113   parr and their protection against furunculosis after i.p. infection with *A. salmonicida*.

114   **2. Materials and Methods**

115   *2.1. Diets and fish husbandry*

116   The dietary trial was carried out at the Aquatic Research Facility (ARF), Institute of

117   Aquaculture, University of Stirling and lasted 177 days. The feeding trial started in June, 2013

118   and ended in December 2013. The fresh water system consisted of twelve 100 l circular tanks

119   supplied with flow-through water at a rate of $1.5 \, l \times min^{-1}$. Water temperature was maintained

120   at $12 \pm 1°C$ (ambient temperature of $12 \pm °C$ for the first 3 months of the study and application

121   of heating later on Day 115 of the feeding trial to maintain the temperature constant throughout

122   the study), whilst photoperiod was constant to prevent smoltification (12 hours of light: 12

123   hours of darkness). Dissolved oxygen, ammonia, nitrate, nitrite and pH were monitored and

124   remained within limits recommended for Atlantic salmon. Prior to the trial unvaccinated S1

Atlantic salmon parr (AquaGen QTL eggs - AquaGen Ltd, Kilmacolm, Scotland - selected for improved growth and resistance to IPNV) purchased from Scottish Seafarms Ltd (Dumfries, Scotland, UK) previously maintained on a commercial BioMar (BioMar Fishes Ltd, Grangemouth, Scotland) diet (BioMar Inicio PLUS) were allowed to acclimate for a week within two stock tanks, during which time they were maintained on a commercial EWOS (EWOS Ltd, Westfield, Near Bathgate, Scotland) diet (EWOS micro). The fish were then randomly allocated into the twelve trial tanks, each tank containing 130 individuals in which they were allowed to acclimatize for 7 days. The fish had an average weight of 9.3 g at the start of the trial. The fish were then starved for two days and were subsequently fed a mixture of the commercial feed and the trial diets they were assigned to. The trial diets contained different levels of protein from SPC (35, 58 and 80% of protein from SPC) replacing FM and were manufactured by EWOS Innovation, Dirdal, Norway. Protein/fat ratios were kept constant (~3.0), while methionine, lysine, L-threonine and phosphorus (P) supplementation increased concomitantly with increased dietary SPC inclusion. Each dietary treatment included four replicate tanks. Dietary formulations are presented in Table 1. Parr were acclimatized to the trial feeds for 3 days prior to the start of the trial. The trial lasted for almost 6 months (177 days) during which fish were fed on the diets to satiation twice daily at 09.30 and 16:30 hours. During feeding the outlets of the tanks were blocked. Satiation was judged to have been achieved when almost 30 pellets were not eaten. Uneaten pellets were then collected through siphoning and feed intake was calculated by subtracting the number uneaten from supplied pellets. The average weight of each pellet was calculated by weighing 8×500 pellets of each diet. Eight fish per tank were sampled on Day 92 of the feeding trial prior to vaccination with a commercial anti *A. salmonicida* and infectious pancreatic necrosis virus vaccine (Alpha-Ject 2-2, Pharmaq) to monitor their immune status. Briefly, blood from 8 fish per tank was collected from the caudal vein into non-heparinised syringes and then transferred into 1.5ml eppendorf

tubes. The blood was allowed to clot at 4° C and then 250μl of serum from the first four fish

were pipetted into an eppendorf tube creating a pool of serum collected from 4 individuals per

tank. Two serum pools per tank were obtained, from which multiple aliquots of 50 μl were

created for the performance of immunoassays. Moreover, two pools of head kidney samples

from 4 fish/tank were obtained for the isolation of head kidney macrophages (HKM) and the

determination of HKM respiratory burst and phagocytic activities as described below. After

the first sampling the bulk weights of the fish in each tank were measured for the assessment

of their growth performance and approximately 80 fish per tank were divided between the

original set of tanks and another set of 12 replicate tanks with the ones kept in the original set

of tanks being vaccinated with the above vaccine and the salmon parr transferred to the

replicate set of tanks being injected with 0.02 M phosphate buffer saline (PBS) (0.15 M NaCl,

pH 7.2). Conditions in all tanks were kept constant to the previous period. The remaining

salmon parr (~40 fish distributed in a third set of 3 tanks -1 tank per diet-) were used to establish

the lethal dose of bacteria giving 70% mortalities of fish intraperitoneally infected with *A.

salmonicida* (100μl). Pools of serum samples (2 serum and 2 head kidney pools from 4 fish per

tank) were taken at 2 days post vaccination (2 dpv) (serum samples from only vaccinated

individuals/head kidney samples from both vaccinated and PBS-injected salmon) (Day 94 of

the feeding trial) and at 62 dpv (Day 154 of the feeding trial-sampling of vaccinated and PBS-

injected salmon). Measurements of salmon bulk weights in the tanks were recorded on Day

154 for growth evaluation. The fish were weighed to the nearest 0.1g. Prior to any experimental

procedure (e.g. weighing, measuring, vaccinating and challenging) all fish were anaesthetized

using MS222 (Tricaine Methanosulphonate, Pharmaq Ltd, Fordingbridge, Hampshire, UK) (50

mg $\times$ l^{-1}). After the experimental procedure the fish were placed in clean aerated water and

allowed to recover (usually within 5 min) before being returned to their tank. Measurements of

fish weight and length were made throughout the experiments. Where fish required to be

175   sacrificed for blood and tissue sampling, they were anaesthetized with MS222 (100 mg $\times$ ml$^-$

176   ^{1}).

177   *2.2. Disease resistance*

178   On Day 154 of the feeding trial (62 dpv), twenty five salmon from each tank of vaccinated

179   and PBS-injected fish were removed and stocked in another two sets of 12 replicate tanks in

180   the ARF. The tanks used were also circular fiberglass tanks supplied with flow-through fresh

181   water as described above. The fish were housed under a controlled photoperiod (12 h of light:

182   12 h of darkness) at a controlled temperature of 13-15ºC. Seventy five hours before *A.*

183   *salmonicida* was administered; a fresh culture of the passaged bacterium was prepared on a

184   blood agar plate. Twenty seven hours before the commencement of the challenge, seven

185   bacterial colonies were cultured in tryptone soy broth (15ºC for 18 h). Subsequently the bacteria

186   were washed twice with sterile PBS with intermediate centrifugation (3500 $\times$ g, 10 min). The

187   OD of the bacterial suspension was then adjusted to 1.0 at 610 nm (6×10^8 cfu $\times$ ml^{-1}), and

188   serially diluted to 0.25×10^{-7} (corresponding to $\sim 2 \times 10^2$ cfu $\times$ ml^{-1}), which was the dilution

189   found to give approximately 70% mortalities in salmon parr in a pre-challenge trial. Cell

190   densities were confirmed by distributing eight 25 µl drops of each one of the obtained serial

191   bacterial suspensions (1.0×10^{-7}, 0.25×10^{-7}, 0.5×10^{-7}, 1.0×10^{-6}) onto tryptone soy agar

192   plates (TSA) (Sigma-Aldrich) and colonies counted after 48 h. One-hundred microlitres of the

193   0.25×10^{-7} bacterial suspension (corresponding to and 2×10^1 cfu $\times$ fish^{-1}) was i.p. injected

194   into each Atlantic salmon after anaesthetizing them (benzocaine, 30 mg $\times$ l^{-1}). Specific

195   mortalities were confirmed by culturing kidney swabs onto TSA and checking colonial

196   morphology. The challenge was terminated after 22 days, at which time mortalities had ceased.

197   *2.3. Growth performance assessment*

198 Salmon growth performance was assessed, through the application of the following formulae

199 to the data:

200 Feed intake:

201 $$FI\left(\frac{g}{day}\right) per\ fish = \frac{Weight\ of\ feed\ given - Weight\ of\ feed\ collected}{Number\ of\ fish \times Number\ of\ days}$$

202 FCR:

203 $$FCR = \frac{Weight\ of\ feed\ given - Weight\ of\ feed\ collected}{W1 - W0}$$

204 Weight gain:

205 $$WG\left(\frac{g}{day}\right) = \frac{Weight\ gain(g)}{Number\ of\ days}$$

206 Specific Growth Rate:

207 $$SGR = \left(\frac{lnW1 - lnW0}{Number\ of\ days}\right) \times 100$$

208 Thermal Growth Rate:

209 $$TGC = \left(\frac{\sqrt[3]{W1} - \sqrt[3]{W0}}{(t \times T)}\right) \times 100$$

210 In the above formulae W0 and W1 is the initial and the final fish mean weights in grams.

211 **2.4. Head kidney macrophage isolation, respiratory burst and phagocytic activity by head**

212 **kidney macrophages**

213   For the isolation of HKMs, the head kidney was teased through a 100 µm nylon mesh

214 (BD Falcon; BD Biosciences, Franklin Lakes, NJ, USA) into 2.5 ml L-15 containing 40 µl of

215 heparin (10 IU $\times$ ml^{-1}). The mesh was rinsed with 2.5 ml of the medium and the cell suspension

216 placed on ice. HKM phagocytic activity and levels of O^{-2} production in HKM suspensions by

217 the conversion of nitroblue tetrazolium (NBT; Sigma-Aldrich) to formazan were measured

218 following the method described by Secombes [27], with modifications described by Korkea-

219 Aho et al. [28].

220   For the measurement of HKM phagocytic activity, duplicate 100-μl cell samples were

221   placed on glass slides and incubated for 1 h at 15°C to allow macrophages to attach. After this

222   time, non-adherent cells were removed by washing the slides three times with L-15 medium.

223   Baker's yeast resuspended in L-15 medium at 5 mg ml^{-1} (100 μl) was added to one of the

224   samples on the microscope slide. An equal volume of L-15 medium was added to the other

225   sample on the same slide as a negative control. Samples were incubated for 1 h at 15°C to allow

226   phagocytosis to proceed. The slides were then washed three times with L-15 medium before

227   100-μl volumes of 100% methanol were added for 5 min. Slides were washed three times with

228   70% methanol and stained with rapid Romanowsky stain (Raymond A Lamb, Eastbourne, UK).

229   The slides were viewed at $\times$ 1000 magnification, and 100 macrophages were counted per

230   sample. The phagocytic activity was determined as the percentage of macrophages performing

231   phagocytosis (% phagocytosis) and as the number of yeast cells engulfed by each macrophage

232   (phagocytic index).

233   For the estimation of HKM respiratory burst activity, one hundred μl of macrophage

234   suspension was added to the 96-well plate (Iwaki, Tokyo, Japan), incubating at 15°C for 2 h to

235   allow cell attachment. The supernatant was removed and wells washed three times with L-15.

236   After washing, 100 μl of L-15 containing 1 mg $\times$ ml^{-1} NBT was added to three replicate wells,

237   and this together with phorbol myristic acetate (1 μl $\times$ ml^{-1} PMA) was added to another three

238   replicate wells, while 100 μl of lysis buffer (citric acid, 0.1 mol$\times$ l^{-1}; Tween 20, 1.0 % (v⁄v);

239   crystal violet, 0.05 % (w⁄v); Sigma-Aldrich) was added to two additional replicate wells. The

240   plate was incubated for 60 min at 15°C, the medium removed and cells fixed with 100 % (v⁄v)

241   methanol for 2–3 min before washing three times with 70 % (v/v) methanol. The plates were

242   air-dried before adding 120 μl of 2 M potassium hydroxide (Sigma-Aldrich) and 140 μl of 2 M

243   dimethyl sulfoxide (Sigma-Aldrich) to each well to dissolve the resulting formazan. The

244   absorbance was determined at 610 nm using an automated multi-mode microplate reader

245   (Synergy HT; BioTek Instruments, Winooski, VT, USA). The number of macrophages

246   attached to the plate was determined by counting the average number of nuclei released by the

247   addition of lysis buffer for two replicate wells. The number of released macrophage nuclei was

248   achieved using a Neubauer chamber, by counting the number of nuclei in the 4 sets of the 16

249   corner squares from one grid. The total number of nuclei within the 4 sets of squares was then

250   divided by 4 and then multiplied by the dilution factor giving the number of nuclei $\times 10^4 \times$ ml$^-$

251   ^{1}. The level of respiratory burst was expressed as an absorbance at 610 nm for 10^5 cells $\times$

252   sample^{-1}.

2.5. Determination of serum glucose, protein and lysozyme activity

254   Serum glucose was determined using a CONTOUR blood glucose monitoring system (Bayer

255   HealthCare LLC) according to manufacturer's instructions. Briefly a CONTOUR strip was

256   inserted accordingly into the Contour blood glucose monitor and then 5μl of serum were

257   pipetted onto the blood receiving end of the CONTOUR strip and held for 5 sec until the test

258   result was displayed on the screen of the monitor. Protein content of serum was determined

259   using a Pierce BCA (bicinchoninic acid) protein determination kit (Thermo Scientific, IL,

260   USA) using bovine serum albumin (BSA) as a standard. Serum lysozyme activity was

261   estimated according to the protocol described by Korkea-Aho et al. [28], based on the lysis of

262   lysozyme sensitive *Micrococcus lysodeikticus*.

2.6. Determination of serum total IgM

264   The level of IgM in sera of experimental fish was determined using an indirect enzyme linked

265   immunosorbent assay (ELISA) described by Metochis et al. [29].

2.7. Determination of specific antibody against *Aeromonas salmonicida*

267   An ELISA was used to measure the specific antibody response of Atlantic salmon to the *A.*

268   *salmonicida* vaccine using the method outlined by Metochis et al [22]. Briefly, 96-well

269   Immulon™ 4HBX plates (ThermoScientific, Maine, USA) were coated with 50 µl of 0.05 %

270   w/v poly-L-lysine (Sigma-Aldrich) in 0.05 M sodium carbonate/bicarbonate buffer, pH 9.6 and

271   incubated for 60 min at 21°C. Plates were then washed twice with a LSWB. *A.salmonicida*

272   (Hooke) in 0.1M PBS was added to the wells at 100 µl × well^{-1} and plates incubated overnight

273   at 4°C. Fifty microliters per well of 0.05 % v/v glutaraldehyde in PBS was added to the bacteria

274   and the plate incubated at 21°C for 30 min before washing three times with LSWB. Non-

275   specific binding sites were blocked by incubating plates with 3% w/v skimmed milk powder

276   in water at 21°C for 120 min. After washing the plates three times with LSWB, 100 µl of

277   serially diluted fish serum diluted in 1 % casein (from 1: 50, 1: 200 and 1: 1000) was transferred

278   to the ELISA plate, which was then incubated overnight at 4°C. Both positive (serum pools

279   from challenged salmon survivors which have been vaccinated prior to challenge) and negative

280   controls (serum blanks/ pooled serum from naïve salmon) were also added to each plate. Plates

281   were washed five times with HSWB with a 5 min soak on the last wash. Anti-rainbow

282   trout/Atlantic salmon IgMmonoclonal antibody (F11-monoclonal anti trout/salmon IgM -

283   Aquatic Diagnostics Ltd, Stirling, Scotland) was then added and plates were incubated at 21°C

284   for 60 min. The steps followed until the development of the plates were the same with those

285   described above. The percentage of specific antibody production was estimated by the

286   comparison of positive (pooled serum from vaccinated and challenged salmon, 100 % antibody

287   production) and negative controls (pooled naïve salmon serum, 0% antibody production) and

288   was expressed as percentage of specific antibody production.

289   *2.8. Measurement of alternative, classical and overall complement activity*

290   Salmon antiserum against sheep RBC was produced by immunising fish i.p. with 10^9 sheep red

291   blood cells (SRBC) in PBS (0.15 M phosphate-buffered saline, pH 7.2). Four weeks after

292   priming a booster injection (10^9) was given, and two weeks later, fish were bled. Control fish

293   were injected with PBS. Endogenous complement activity of anti-SRBC salmon serum was

294 inactivated by heating at 50°C for 30 min and the anti-SRBC serum was diluted with 0.1%

295 Gelatin-Complement Fixation Buffer (G-CFB) (1 tablet of Oxoid complement fixation tablets

296 in 100 ml of warm water and 0.1 g of gelatin from Sigma-Aldrich) with 20mM EDTA. Diluted

297 anti-SRBCs were then stored at -20°C. Sheep blood (Oxoid) was stored at 4°C in Alsever's

298 solution (1: 1) for 1 week before use. The SRBCs were used to determine lysis by the alternative

299 complement pathway (ACP), while SRBCs, sensitized (60 minutes, 37°C) with pooled and

300 diluted (1: 400) salmon anti-SRBC serum, was used for determination of total (TC) and

301 classical complement pathway (CCP) activity. Buffer for the AC was 0.01 M EGTA-Mg-G-

302 CFB and for determination of the total and classical haemolytic activity G-CFB. Tests were

303 done in round-bottomed 96-well microtiter plates (Sterilin).Briefly complement activity

304 determination was based on methods described by Yano et al. [30-31] with modifications.

305 Briefly serum was diluted four times in double serial dilutions accordingly (starting from 1:4

306 for the estimation of AC activity and 1: 16 for the estimation of TC and CC activity) and 25 μl

307 of each dilution was added to each well of a non-absorbent U-well micro-plate (Sterilin) in

308 duplicate. Ten microliters of 0.5 % SRBC suspension was added to each serum dilution.

309 Controls on each plate comprised 0.1 % anhydrous Na_2CO_3 (v/v) (100 % lysis) replacing

310 serum. G-CFB replacing serum (0 % lysis) and serum blanks (duplicate wells of serum

311 dilutions with G-CFB replacing SRBC suspension). The plates destined for the estimation of

312 TC and CCP activity also included, a CC control sensitization of SRBC with non-immune

313 pooled carp serum and a standard complement sample (serum pool) for correction of plate

314 differences were included. Microtitre plates were incubated at 22°C for 90 min with constant

315 shaking and the reaction terminated by the addition of 140 μl G-CFB with 20mM EDTA,

316 followed by centrifugation at $1500 \times g$ to spin down the remaining SRBCs. After centrifugation

317 100 μl of the supernatant from each well was transferred to a new flat-bottomed 96-well non-

318 absorbent micro-titre plate (Sterilin). The absorbance of the wells was read at 450 nm using a

319   micro-plate reader (Synergy HT; BioTek Instruments, Winooski, VT, USA) and the percentage

320   lysis of SRBCs calculated. The absorbance values of samples were corrected by subtracting

321   the absorbance of the sample blank control (0% haemolysis).

322   ***2.9. Diet composition analysis***

323   Dietary crude fat was determined following acid hydrolysis using a Soxtec System 1047

324   hydrolysing unit (Tecator Application note 92/87) followed by exhaustive Soxhlet extraction

325   using petroleum ether (40–60°C boiling point) on a Soxtec System HT6 (Tecator application

326   note 67/83)as described by Bell et al. [32]. Dry weight and ash contents of diets were

327   determined after oven-drying the samples to constant weight (at 100 ºC) and by ashing dried

328   samples in an oven at 550°C [33]. Dietary energy content was determined through bomb

329   calorimetry [33]. For the determination of phytic acid and phytic acid bound P content in the

330   diets a Megazyme Phytate/Total Phosphorus Assay kit (Megazyme, Ireland) was used. Dietary

331   energy content was determined through bomb calorimetry [33].

332   Dietary carbohydrate was determined following a modified Dubois phenol sulphuric

333   method. Dietary fibre was determined after subjecting defatted dietary samples (3 washes with

334   petroleum ether) within pre-weighed organic capsules, to acid (with 1.25% sulphuric acid

335   solution)and alkaline hydrolysis (with 1.25% sodium hydroxide solution) for 35 min each,

336   using a Fibertec system 1020 hot Extractor. Following one last defatting step (3 washes with

337   petroleum ether), the samples were ashed at 600°C in a muffle furnace (Gallenkamp Muffle

338   Furnace) for 4 hours, cooled in a desiccator and reweighed (W2).   Extracted fibre was

339   expressed as percentage of the original undefatted sample and calculated according to the

340   formula:

341
$$Fibre(\%) = \frac{(W1 \times 1.0011) - Capsule\ weight - (W2 - 0.0025)}{Sample\ weight\ (g)} \times 100$$

342 Where W1 is the initial weight of the unprocessed dietary sample and W2 is the weight after

343 processing.

344   Dietary minerals and phosphorus were determined using inductively coupled plasma

345 mass spectroscopy (ICP-MS) with collision cell technology (CCT) (Thermo X Series 2).

2.10. Statistics

347   Growth and immunological data were examined using a one-way analysis of variance

348 (ANOVA), general linear model, and pairwise comparison (Tukey-test) of means. All

349 statistical tests were performed using Minitab statistical software (Version 17[©], University of

350 Stirling, 2016). Differences were considered statistically significant at *p values < 0.05*.

351 Statistical differences were examined between naïve dietary groups prior to vaccination, the

352 vaccinated dietary groups at 2 and 62 dpv and the PBS-injected dietary salmon at 2 and 62

353 dpPBSinj. Serum pools were used as statistical units (two serum and/or HKM pools from 4

354 fish per tank thus two pools per tank resulting in eight pools per treatment). Data are presented

355 as means ± SEM. The analysis of the survival data from the disease challenge trial was

356 performed with Cox regression (Cox proportional hazard modelling) in SPSS statistical

357 software (IBM SPSS Statistics 21, University of Stirling, 2016) using time-to-event (e.g. the

358 time at which a subject in the 30-day challenge period survived – data for each fish were

359 recorded) and status for each fish (dead =1 or alive =0) variables (individual fish per treatment

360 and time-to-event, were used as statistical units – from the former parameters the coefficients

361 *Exp (B)* e.g. hazard ratios, per treatment group were estimated) and the level of protein from

362 SPC in the dietary treatments as the covariate. Differences were considered statistically

363 significant at *p values* < 0.05 while the coefficient *Exp (B)* was also recorded for the assessment

364 of potential positive or negative effects of increased dietary SPC levels in the resistance of

365 salmon to furunculosis (*Exp (B)* or Hazard Ratio is the factor by which the hazard **-the presence**

366 **of mortalities upon infection-** for a dietary group is increased or decreased; *Exp (B)* values =

1 reveal no changes in salmon resistance and/or hazard ratio -*HR*-, values > 1 reveal an increment in *HR* and deterioration of its disease resistance and values < 1 reveal a decrease in *HR* and an improvement of salmon resistance to furunculosis)

3. Results

3.1. Growth performance

Salmon performance data are given in Table 2. Overall, negligible mortalities (< 0.1 %) were observed in the three dietary groups prior (Day 92) and post vaccination/PBS-injection (Day 154) (Table 2). SPC80 salmon exhibited reductions in feed intake and FCR at Day 92. Significant decreases for all growth performance indices (mean weights, WG, SGR, TGC) were observed for both SPC58 and SPC80 salmon in comparison to SPC35 fish prior to vaccination/PBS injection.

At Day 154, reductions in FCR persisted in SPC80 salmon compared to the SPC35 group. In addition decreased mean weights, WG, TGC and SGR were demonstrated for the SPC80 group in comparison to SPC35 salmon at both vaccination states on Day 154, while no differences were detected between SPC58 and SPC35 salmon for any of the performance parameters.

3.2. Immune Responses

The data of the estimated immunological responses are presented in Table 3. Serum proteins were only affected by time or state and not by dietary levels of SPC. A sharp decrease in serum protein levels was exhibited in vaccinated salmon at 2 dpv while at 62 dpv serum protein increased compared to the levels at 2 dpv. Nevertheless, serum protein concentrations were found to be lower than their initial pre-vaccination serum concentrations. On the contrary, serum protein levels in PBS-injected fish doubled at 62 days post PBS injection (62 dpPBSinj) when compared to naïve salmon.

391   Serum total IgM concentrations did not exhibit any differences among the dietary salmon

392   groups. While serum total IgM in naïve and PBS-injected salmon were found to be similar, in

393   vaccinated salmon total IgM levels demonstrated a decrease at 2 dpv compared to pre-

394   vaccination values, whereas at 62 dpv total IgM increased 4-fold, compared to naïve salmon

395   serum concentrations. Specific IgM was measured at 62 dpv and no differences were detected

396   among the three dietary groups.

397   Lysozyme activity was another immune response exhibiting no changes among the

398   dietary salmon groups. Both naïve and PBS-injected salmon at Day 154 exhibited similar

399   lysozyme activities. An increment in average lysozyme activity was obtained at 2dpv compared

400   to the pre vaccination levels, followed by a further increase at 62dpv. Serum glucose

401   concentrations did not show any differences among dietary groups. Moreover, similar glucose

402   concentrations were detected in naïve and PBS-injected salmon serum. However at 2 dpv,

403   glucose levels were found to be higher than in pre-vaccinated fish, while at 62 dpv glucose

404   levels in the vaccinated groups were lower compared to naïve salmon.

405   At Day 63 prior to vaccination/PBS-injection, SRBC haemolysis due to TC and CC

406   activity demonstrated significant reductions in SPC58 compared to SPC35 (both *p* values for

407   CC and TC were equal to 0.02) salmon while no differences were detected between the SPC80

408   and SPC35 groups. Alternative complement activity on the other hand did not show significant

409   differences among the treatment groups. No differences in the complement activities were

410   observed at 62 days post PBS-injection among the dietary treatments. However, a decreasing

411   trend in AC activity was observed in fish receiving increasing dietary SPC levels (*p* value =

412   0.06). On the contrary, significantly lower AC activity was observed for SPC80 salmon at both

413   timepoints post vaccination compared to SPC35 (*p values*: 0.02 at 2 dpv and 0.04 at 62 dpv)

414   salmon while SPC58 salmon exhibited lower activity only at 2 dpv (*p value* = 0.02). No

415 differences in total complement (TC) activity were exhibited among the dietary groups of

416 vaccinated and PBS-injected salmon.

417 No differences in PMA-stimulated and non-stimulated HKM respiratory burst and

418 phagocytic activity among the dietary groups of salmon prior to vaccination/PBS-injection,

419 were detected. For vaccinated salmon, the estimated values for all the HKM responses among

420 the dietary groups presented no differences, with respiratory burst activity, phagocytic index

421 levels and phagocytosis % increasing sharply at 2 dpv compared to the values recorded prior

422 vaccination and decreasing at 62 dpv below the latter values. For PBS-injected salmon,

423 respiratory burst was similar to the ones obtained for vaccinated salmon at 2 and 62 dpv

424 exhibiting an almost equal increase at 2 dpPBSinj, followed by a subsequent reduction, at levels

425 lower than the ones determined for naïve salmon except for PMA-stimulated HKM, which

426 presented higher activity at 62 days post injection compared to naïve fish. Significantly lower

427 phagocytic activity (phagocytosis % and phagocytic index) were detected between SPC58 and

428 SPC80 salmon compared to the SPC35 group at 62dpPBSinj (*p value* = 0.03).

429 *3.3. Disease resistance trial*

430 No mortalities were observed for any of the dietary groups vaccinated against *A. salmonicida*

431 after challenging them with the bacterium. The raw data of PBS-injected salmon cumulative

432 survival during the experimental infection are presented in Fig. 1. Mortalities were obtained

433 from all dietary groups in PBS-injected and subsequently challenged Atlantic salmon parr.

434 Mortalities from these fish first started to occur at 6 days post challenge, but only for the SPC35

435 salmon group. On Day 7 post-challenge the first mortalities from SPC58 salmon were

436 observed, while on Day 8, mortalities from the SPC80 group of salmon also started to occur.

437 Mortalities ceased on Day 19 post-challenge. At this time, the mortality rate for the SPC35

438 group from all tanks corresponded to 44%. A death rate of 34% was observed for the SPC58

439 while a 29% mortality rate was recorded for SPC80 salmon. Statistical analysis revealed no

18

significant differences among the dietary salmon groups (*p value* = 0.07) and a slight reduction in the hazard ratio (*Exp (B)* = 0.76 − non-significant improvement of salmon resistance to furunculosis) of salmon fed on the diets the highest SPC levels (SPC80).

4. Discussion

In the present trial, significant reductions for most performance indices (FCR, average weight, weight gain, SGR and TGC) were observed for both vaccinated and PBS-injected SPC80 compared to their SPC35 counterparts while no differences between the latter dietary group and SPC58 salmon at both states were obtained at Day 154 (62 dpv/dpPBSinj). Considering the initial reductions in SPC58 salmon growth in comparison to the SPC35 group (9-30g fish), it is suggested that larger size salmon parr of ~30 g with a more developed digestive system can make a more efficient use of the SPC58 diet compared to smaller size parr of 9g or that salmon receiving this diet requires an adaptation period before accepting and start utilizing efficiently the nutrients in this type of feed [17, 34-36]. On the contrary, the levels of SPC in the SPC80 diet were overwhelming for salmon parr which never manage to recover the initial reductions in growth performance when compared to SPC35 salmon. Growth reductions in fish fed diets with very high levels of SPC are generally attributed to the increased amounts of phytic acid (Table 1), decreasing the digestibility and availability of dietary nutrients [37] and the lower concentrations of several key nutritional components found abundantly in FM and scarcely or absent in plant proteins (including macro and trace minerals, sterols and non-nitrogen compounds), compromising feed acceptability, FCR and growth in fish [13,14, 38-41]. Compromised feed acceptability was apparent during the first period of the study for SPC80 compared to SPC35 salmon, while numerical decreases persisted during the full course of the study. Moreover, decreased FCR was apparent for the SPC80 group at all timepoints.

Herein, the determination of serum protein levels was used to evaluate the general condition of experimental salmon [42], whereas serum glucose was measured for the evaluation

19

465 of the general stress status of fish from different dietary groups [43]. Moreover, the assessed

466 immune responses are considered salient components of salmon defence mechanisms against

467 disease. Lysozyme and macrophage phagocytosis followed by oxygen radical production, are

468 important antimicrobial agents [27-28], while complement and total and specific IgM are

469 linked with the neutralisation and opsonisation of various pathogens [44-45]. Thompson et al.

470 [46] suggested that measuring defence mechanisms prior to challenge only represents resting

471 levels. However, measuring immune function after immune stimulation (either through

472 challenge or vaccination) may highlight dietary modifications that are not previously evident.

473 This is further highlighted in mammalian research, where studies have shown that nutrients are

474 preferentially directed towards the immune system, rather than growth, during times of

475 infection [47]. This includes the distribution of amino acids to the liver for synthesis of acute

476 phase proteins [48] and suggests suboptimal nutrient intake prior to infection may result in a

477 diminished immune response. It therefore seems a logical step to evaluate the immune function

478 of the fish after its dietary protein source has been altered. For this reason, salmon parr

479 receiving the experimental diets in the present trial were vaccinated and then challenged with

480 *A. salmonicida*.

481   While most of these immunological parameters (serum lysozyme, protein, total IgM,

482 head kidney macrophage phagocytic activity and oxygen radical production) have been

483 previously shown to be modulated by dietary change in various teleosts (summarized by Kiron

484 [44]), no differences compared to the commercial type control SPC35 diet occurred prior or

485 post-vaccination in the present study. Similar to the current trial, Bransden et al. [49] reported

486 no differences in lysozyme activity, plasma concentrations of total IgM, total protein or glucose

487 levels of non-immunized salmon parr fed on diets where dehulled lupin meal replaced 40% of

488 FM. Furthermore, in line with the present study, Jalili et al. [18] demonstrated no differences

489 in serum lysozyme levels of non-immunized rainbow trout (*Oncorhynchus mykiss*) fed on diets

490 fully based on mixed plant proteins. Rumsey et al. [20] reported increased lysozyme activity

491 in rainbow trout fed SBM diets. Contrary to this, Fahrangi & Carter [50] revealed decreased

492 serum protein levels in rainbow trout receiving 30, 40 and 50 % of dehulled lupin meal,

493 compared to trout fed 10% dehulled lupin meal, while no changes were detected in serum

494 glucose levels. Increased lysozyme activity at both points after vaccination for all dietary

495 groups of salmon is indicative of both stress induction and immune stimulation and was not

496 apparent in naïve fish. Vaccination is a stressful process, which could explain the sharp increase

497 in serum glucose at 2 dpv [51-52]. Furthermore, the stress-related reduction in fish appetite due

498 to vaccination could explain the concomitant reduction in serum protein and total IgM levels

499 observed at 2 dpv in vaccinated salmon [53]. The observed initial reduction in serum total IgM

500 could also be related to the formation of antibody-antigen complexes, reducing the number of

501 free circulating natural antibodies at 2 dpv [54-55]. The reduction in serum glucose levels at

502 62 dpv, below those of pre-vaccinated or PBS-injected salmon at 62 days post injection

503 demonstrates the reduced responsiveness to acute stressors (e.g. sampling processes such as

504 netting and exposure to anaesthetic) of salmon subjected to higher stress for a prolonged time

505 period (e.g. vaccinated salmon vs PBS-injected salmon due to immune stimulation) [56-57].

506 However, the 4-fold increase in total IgM for all dietary groups at 62 dpv is an indication of

507 the efficacy of vaccination [53, 58], and the absence of polyetiological stress during the study,

508 which could have compromised this response [52]. The increase of total protein is also

509 indicative of salmon appetite recovery at 62 dpv [53]. In a previous study performed by

510 Metochis et al. [22], higher plasma total IgM and lysozyme activity in SPC50 and SPC65

511 compared to SPC35 salmon prior to vaccination (Day 63 of feeding), 7 dpv (Day 70) and 34

512 dpv (Day 97) were demonstrated. Contrarily lower levels to former two groups were

513 demonstrated for SPC80 salmon, similar to those observed in SPC35 fish. While IgM levels

514 prior to and after vaccination followed similar patterns in the two studies, lysozyme activities

515 presented different post vaccination patterns. The observed differences are discussed further

516 below (paragraph 7 of Section 4).

517   No effects of the SPC inclusion levels on specific antibody production were detected,

518 which is in line with the data from the study by Metochis et al. [22], on increasing dietary SPC

519 levels on larger size Atlantic salmon parr. Kiron et al. [59-60] reported no changes in the

520 specific antibody levels of rainbow trout fed on different dietary protein levels, suggesting that

521 specific antibody production does not seem to depend on dietary protein quantity. This could

522 explain why in the present trial, differences in protein intake attributed to the reduced feed

523 intake or the presence of phytic acid which is known to adversely affect protein digestibility,

524 did not affect the production of specific antibodies. Moreover, many studies on the effects of

525 dietary or injectable immuno-stimulants have found no effect on specific antibody production

526 in fish (summarized by Anderson [61] and Gannam & Schrock [62]), which could be an

527 indication that increasing dietary levels of plant proteins with potential immunostimulatory

528 effects, do not promote specific antibody production and that their activity lies on the

529 stimulation of innate immune components.

530   Complement activity appeared to be the most eminently affected immune response by

531 increased dietary SPC inclusions, during the course of the study, in accordance to previous

532 studies [19, 22, 63]. While no changes in AC activity among the dietary groups were observed,

533 lower CC and TC (the sum of alternative, classical complement activities) activities were

534 detected in salmon fed increased dietary SPC levels at Day 92, prior vaccination. In similar

535 studies, increased or unaffected AC activity were reported in gilthead sea bream (*Sparus*

536 *aurata*) and rainbow trout respectively, in naïve fish fed up to 50% of protein from plant

537 ingredients, while decreased activity was observed in fish fed on diets with over 70% of protein

538 from such feedstuffs [18-19]. Alternative complement activity is considered as a major

539 component of salmon' innate immunological defences against diseases, depending on serum

22

540   Mg availability for its activation [64-66]. Classical complement activity, on the other hand, is

541   a component of acquired immunity, enhanced upon specific immune stimulation and increased

542   serum antibody presence, having a requirement for both Mg and Ca for its activation [64-66].

543   Increased dietary Mg levels in higher SPC inclusion diets could have attributed to the absence

544   of differences in AC activity among the dietary groups despite any proposed reductions in

545   mineral uptake due to reduced feed intake and increased dietary phytic acid concentrations [13-

546   14, 37]. On the contrary, lower dietary Ca in high SPC inclusion diets could have influenced

547   reductions in CC activity [64]. Moreover, potential reductions of protein and/or amino acid

548   intake in high SPC inclusion groups (due to higher dietary phytic acid levels) could have

549   influenced metabolic changes, favouring AC protein production over CC proteins, in order not

550   to compromise salmon innate immune response, the first line of defence against diseases [22,

551   37, 67-69]. Overall, lower complement activities were detected after vaccination compared to

552   pre-vaccination levels while the highest activities were exhibited in PBS-injected salmon at

553   Day 154 allegedly due to their naivety to immune challenges translating to reduced stress,

554   higher feed intake, higher growth and higher circulating protein levels [51, 70]. In general,

555   lower complement activity after vaccination, could be attributed to the formation of

556   complement complexes with the vaccine, as was the case for serum total antibodies,

557   diminishing the concentration of complement proteins in vaccinated salmon sera [53-55].

558   Moreover, the reduced levels of alternative complement activity for SPC58 and SPC80

559   compared to SPC35 salmon could highlight suboptimal nutrient uptake prior to vaccination

560   [46]. Suboptimal protein and or amino acid uptake during the primary (pre-injection) period

561   could have also influenced the trends of decreasing AC activity in naïve fish receiving higher

562   dietary SPC levels at Day 154 [46, 67-68]. At 62 dpv average CC complement activity for all

563   groups was recovered at higher levels than at 2dpv revealing stimulation of the specific

564   immunity, in accordance to previous studies [53, 55, 58]. The observed increments in CC

23

565 activity at 62 dpv were more pronounced for high dietary SPC groups compared to SPC35

566 salmon. In a previous study, Metochis et al. [22] reported significantly higher plasma

567 haemolytic activity in salmon fed high SPC inclusion diets at 97 days post feeding (and 34

568 dpv), while no differences were observed prior to (Day 63) and at 7 dpv. In the same study,

569 salmon haemolytic activity remained fairly constant prior to and at 7 dpv while showing an

570 increase at 34 dpv, similar to the evolution of the TC haemolytic response patterns presented

571 here.

572 While most of the immune related responses measured for HKMs did not show

573 differences among the dietary groups prior to and post vaccination, higher HKM phagocytosis

574 percentages were detected in SPC58 salmon injected with PBS at 62 dpPBSinj compared to

575 their SPC35 counterparts. This shows that inclusion of 58% of amino acid and phosphate

576 supplemented dietary protein from SPC, could have a stimulatory effect on HKM motility

577 which is reduced at higher dietary SPC inclusion levels. Previously, Metochis et al. [22]

578 reported no differences in the respiratory burst activity of Atlantic salmon fed diets with

579 increasing dietary SPC inclusions. However, the HKM respiratory response patterns observed

580 in the former study were different from the ones recorded here and they are discussed below in

581 the next paragraph. Rumsey et al. [20] demonstrated both increased phagocytosis and

582 respiratory burst activity by circulating leucocytes in rainbow trout fed on SBM. However,

583 those findings were attributed to inflammatory and hypersensitivity processes, since SBM

584 ANFs are linked with intestinal inflammation [16]. Previously, Burrells et al. [21] reported that

585 HKM respiratory burst in rainbow trout fed on diets containing 10-50 % of SBM remained

586 unaffected, whereas inclusion levels of up to 80% caused a reduction in HKM responses. Sitja-

587 Bobadilla et al. [19], contrary to the present findings, reported higher respiratory burst activity

588 by HK leucocytes in juvenile sea bream fed on nutritionally balanced diets in which 75% of

24

589   FM was substituted with a mixture of different plant protein sources and supplemental amino

590   acids.

591   Discrepancies in the way salmon parr immune responses were affected prior to and post

592   vaccination, their magnitude and differences in the responses of salmon fed increasing dietary

593   SPC levels were not in accordance with the previous study by Metochis et al. [22]. Despite, the

594   high relevance in the experimental design between the two studies, differences in the observed

595   immune responses could be attributed to a number of experimental disparities such as: (A) The

596   use of different salmon breeds (AquaGen salmon selected for improved growth and resistance

597   to IPNV vs Salmo Breed salmon selected for higher growth performance previously) [51]; (B)

598   The use of different commercial adjuvanted vaccines (i.e. liquid paraffin vaccine against

599   furunculosis and IPNV vs montanide vaccine against furunculosis previously) [61]; (C) The

600   concentration and source of dietary P (increasing monocalcium phosphate upon increasing

601   dietary SPC vs diets supplemented with constant amounts of dicalcium phosphate previously)

602   [45 and 71]; (D) The timing of sampling (2 and 62 dpv vs 7 and 34 dpv); (E) The photoperiod

603   applied (12 h dark: 12 h light vs constant light previously) [72-73]; (F) The feeding regime

604   applied (non-intensive: fish fed to satiation twice daily vs intensive: fish fed continuously every

605   435 seconds all throughout the day previously) [74-75]; and (G) The developmental stage of

606   salmon parr used (small size vs large size salmon parr previously) (reviewed by [76]).

607   However, despite the observed differences in the patterns and magnitude of the assessed

608   immune responses in the two studies, both of them have proven that a range of innate and

609   specific immune responses in Atlantic salmon parr fed diets with up to 80% of amino acid

610   supplemented protein from SPC were not compromised compared to fish fed a commercial

611   type control feed with 35% of protein from SPC and constant [22] or increasing P

612   supplementation (present study). Another important finding of the present study is that

613   vaccination can highlight differences in immune responses attributed to dietary changes and

614 which might be masked without stimulation of salmon immunity. The latter finding was also

615 apparent from the results of the previous study by Metochis et al. [22].

616   Salmon were challenged against *A. salmonicida*, on Day 154 of the feeding trial and at

617 64 dpv, in order to prove that the observed data on salmon immune responses pointing at a non-

618 compromised health status were actually meaningful. Challenge with *A.salmonicida* resulted

619 in lower mortality levels (44 %), than expected (~70%) according to the pre-challenge.

620 Reduced virulence for this strain of *A.salmonicida* has been previously observed after long-

621 term storage (6-7 months) of these bacteria in beads at -70ºC or in glycerol at -20ºC (Herath,T.,

622 personal communication and Chalmers, L., personal communication). Another factor that

623 could have influenced the lower number of mortalities in the groups during the challenge period

624 compared to the pre-challenge tests was the fact that potential bacterial dose differences

625 (producing 70% mortalities) due to the larger size of the fish at the challenge timepoint, were

626 not taken into account (reviewed by Tatner [76]). The reason was that very low bacterial doses

627 were required to produce 70% mortalities (LD_{70}) in 32g salmon parr increasing the probability

628 of misestimating the LD_{70} for larger size fish. The absence of mortalities in the vaccinated

629 groups were indicative of the promotion of specific immunity by all treatments and the lack of

630 differences in specific immunity among the dietary salmon groups. The data also suggest that

631 increasing dietary SPC levels were not detrimental for the resistance of naïve salmon to

632 furunculosis, confirming the lack of differences in the assessed immune responses. Similarly

633 to the present findings, Bransden et al. [49] reported no differences in the resistance of salmon

634 parr fed diets with 0 or 40% of FM substitution with dehulled lupin meal when experimentally

635 infected with *Vibrio anguillarum*, whereas Jalili et al. [18] found no differences in the mortality

636 of rainbow trout fed diets with 0, 40, 70 and 100% replacement of FM with plant proteins when

637 challenged against *Yersinia ruckerii*. Krogdahl et al. [16] reported increased survival in salmon

638 fed a diet with 30% of dietary protein from SPC compared to fully FM-fed fish challenged

through cohabitation with *A.salmonicida*. In the previous study, the proposed reason for the increased survival was the observed increase in IgM levels in the intestinal mucosa of SPC-fed compared to FM-fed salmon. Herein, it was shown diets with even higher dietary SPC levels compared to the ones reported by Krogdahl et al. [16] (control diet in the present study was close to the SPC diet used in the latter study) do not seem to affect the immunity or resistance of salmon intraperitoneally infected with furunculosis.

5. Conclusions

Atlantic salmon parr presented a slow but steady adaptation to the diet with 58% of protein from SPC, presenting similar growth performance to the commercial type control diet at 154 days post feeding but that was not the case with the diet with 80% of protein from SPC. On the contrary, replacement of high quality FM protein with high levels of amino acid and phosphate supplemented SPC (80% of dietary protein) did not produce any reductions of the immune responses or the disease resistance of naïve and/or vaccinated salmon against *A. salmonicida,* suggesting no negative effects on immunity. Diets with 58% of dietary protein from SPC produced similar growth and immune responses to the commercial type control feed with 35% of protein from SPC and could be used for the on-growing of salmon parr. However, further challenge experiments against other bacterial, viral and parasitic diseases are required to properly assess the effects of high SPC inclusion diets on the disease resistance of juvenile Atlantic salmon.

664   Mrs Olga Rubio Palladini from the Institute of Aquaculture, University of Stirling for their

665   assistance during the samplings.

REFERENCES

667   [1] G.L. Rumsey, Fish meal and alternate sources of protein in fish feeds. Fisheries 18 (1993) 14–19.

668   [2] FAO, State of world fisheries and aquaculture. Food and Agriculture Organization of the United Nations. Food
669   and Agriculture Organization of the United Nations, Rome, Italy, 2012.

670   [3] S.J. Kaushik, Use of alternative protein sources for the intensive rearing of carnivorous fishes, in: R. Flos, L.
671   Tort, P. Torres (Eds.), Mediterranean Aquaculture. Ellis Horwood, Chichester (United Kingdom), 1990,
672   pp. 125–138.

673   [4] A.G.J. Tacon, Feed ingredients for carnivorous fish species alternatives to fishmeal and other fishery resources.
674   FAO Fish Circ 881 (1994) 35.

675   [5] J.J. Olli, Å. Krogdahl, T.S.G.A.M. van den Ingh, L.E. Brattås, Nutritive value of four soybean products in
676   diets for Atlantic Salmon (*Salmo salar*, L.). Acta Agric. Scand. Sect. A – Anim. Sci. 44 (1994) 50–60.

677   [6] C. Carter, R. Hauler, Fish meal replacement by plant meals in extruded feeds for Atlantic salmon, *Salmo salar*
678   L. Aquaculture 185 (2000) 299–311.

679   [7] NRC, Nutrient Rrequirements of fish - National Research Council. National Academy Press, Washington DC,
680   1993.

681   [8] T. Masumoto, T. Ruchimat, Y. Ito, H. Hosokawa, S. Shimeno, Amino acid availability values for several
682   protein sources for yellowtail (*Seriola quinqueradiata*). Aquaculture 146 (1996) 109–119.

683   [9] M. Peisker, Manufacturing of soy protein concentrate for animal nutrition. Cah. Options Mediterr. 54 (2001)
684   103–107.

685   [10] J.C. Russett, Soy protein concentrate for animal feeds, in: Specialty Products Research Notes SPC-T-47.
686   Central Soya Company, Fort Wayne, Indianapolis, 2002.

687   [11] S.D. Hart, P.B. Brown, Purdue University Department of Forestry and Natural Resources. West Lafayette,
688   Indiana 47907-2061, USA, 2007.

689   [12] S. Refstie, T. Storebakken, A.J. Roem, Feed consumption and conversion in Atlantic salmon (*Salmo salar*)
690   fed diets with fish meal, extracted soybean meal or soybean meal with reduced content of oligosaccharides,
691   trypsin inhibitors, lectins and soya antigens. Aquaculture 162 (1998) 301–312.

692   [13] T. Storebakken, K. Shearer, A. Roem, Availability of protein, phosphorus and other elements in fish meal,
693   soy-protein concentrate and phytase-treated soy-protein-concentrate-based diets to Atlantic salmon, *Salmo*
694   *salar*. Aquaculture 161 (1998) 365–379.

695   [14] T. Storebakken, K.D. Shearer, A.J. Roem, Growth, uptake and retention of nitrogen and phosphorus, and
696   absorption of other minerals in Atlantic salmon *Salmo salar* fed diets with fish meal and soy-protein
697   concentrate as the main sources of protein. Aquac. Nutr. 6 (2000) 103–108.

698   [15] A.-M. Escaffre, S. Kaushik, M. Mambrini, Morphometric evaluation of changes in the digestive tract of
699   rainbow trout (*Oncorhynchus mykiss*) due to fish meal replacement with soy protein concentrate.
700   Aquaculture 273 (2007) 127–138.

701 [16] Å. Krogdahl, A.M. Bakke-McKellep, K.H. Røed, G. Baeverfjord, Feeding Atlantic salmon *Salmo salar* L.
702   soybean products: effects on disease resistance (furunculosis), and lysozyme and IgM levels in the
703   intestinal mucosa. Aquac. Nutr. 6 (2000) 77–84.

704 [17] G.S. Burr, W.R. Wolters, F.T. Barrows, R.W. Hardy, Replacing fishmeal with blends of alternative proteins
705   on growth performance of rainbow trout (*Oncorhynchus mykiss*), and early or late stage juvenile Atlantic
706   salmon (*Salmo salar*). Aquaculture 334-337 (2012) 110–116.

707 [18] R. Jalili, A. Tukmechi, N. Agh, F. Noori, A. Ghasemi, Replacement of dietary fish meal with plant sources
708   in rainbow trout (*Oncorhynchus mykiss*); effect on growth performance, immune responses, blood indices
709   and disease resistance. Iran. J. Fish. Sci. 12 (2013) 577–591.

710 [19] A. Sitjà-Bobadilla, A., S. Peña-Llopis, P. Gómez-Requeni, F. Médale, S. Kaushik, J. Pérez-Sánchez, Effect
711   of fish meal replacement by plant protein sources on non-specific defence mechanisms and oxidative stress
712   in gilthead sea bream (*Sparus aurata*). Aquaculture 249 (2005) 387–400.

713 [20] G.L. Rumsey, A.K. Siwicki, D.P. Anderson, P.R. Bowser, Effect of soybean protein on serological response,
714   non-specific defense mechanisms, growth, and protein utilisation in rainbow trout. Vet. Immunol.
715   Immunopathol. 41 (1994) 323–339.

716 [21] C. Burrells, P.D. Williams, P.J. Southgate, V.O. Crampton, Immunological, physiological and pathological
717   responses of rainbow trout (*Oncorhynchus mykiss*) to increasing dietary concentrations of soybean
718   proteins. Vet. Immunol. Immunopathol. 72 (1999) 277–288.

719 [22] C.P. Metochis, V.O. Crampton, K. Ruohonen, J.G. Bell, A. Adams, K.D. Thompson, The effects of
720   increasing dietary levels of soy protein concentrate and constant dietary supplementation of phosphorus
721   on growth, composition and immune responses of juvenile Atlantic salmon (*Salmo salar* L). Fish Physiol.
722   & Biochem. 42(3) (2016) 807-829.

723 [23] B. Austin, Progress in understanding the fish pathogen *Aeromonas salmonicida*. Trends Biotechnol 15 (1997)
724   131–134.

725 [24] D.H. McCarthy, Some ecological aspects of the bacterial fish pathogen-*Aeromonas salmonicida*. Aquat.
726   Microbiol. Symp. Soc Appl Bacteriol 6 (1980) 299–324.

727 [25] G.W. Klontz, Oral immunization of coho salmon against furunculosis. In: Progress in sport fishery research.
728   Resour. Publ. Bur. Sport Fish. Wildl. U.S.A., 39 (1968) 81–82.

729 [26] J.L. Hodgkinson, D. Bucke, B. Austin. Uptake of the fish pathogen, Aeromonas salmonicida , by rainbow
730   trout (*Salmo gairdneri* L.). F.E.M.S. Microbiol. Lett. 40 (1987) 207–210.

731 [27] C.J. Secombes, Isolation of salmonid macrophages and analysis of their killing activity, in: Stolen, J.S.,
732   Fletcher, T.C., Anderson, D.P., B.S., R., van Muiswinkel, W.B. (Eds.), Techniques in Fish Immunology.
733   SOS Publications, Fair Haven, New Jersey, 1990, pp. 137–154.

734 [28] T.L. Korkea-aho, J. Heikkinen, K.D. Thompson, A. von Wright, B. Austin, *Pseudomonas* sp. M174 inhibits
735   the fish pathogen *Flavobacterium psychrophilum*. J. Appl. Microbiol. 111 (2011) 266–77.

736 [29] B. Magnadottir, B.K. Gudmundsdottir, A comparison of total and specific immunoglobulin levels in healthy
737   Atlantic salmon (*Salmo salar* L.) and in salmon naturally infected with *Aeromonas salmonicida* subsp.
738   *achromogenes*. Vet. Immunol. Immunopathol. 32 (1992) 179–89.

739 [30] T. Yano, H. Matsuyama, K. Tanaka, M. Nakao, Alternative pathway-hemolytic complement titer (ACH50)
740   of porgy *Pagrus major* serum. Bull. Jap. Soc. Sci. Fish. 53 (1987) 1887-1891.

741 [31] T. Yano, Y. Hatayama, H. Matsuyama, M. Nakao, Titration of the alternative complement pathway activity
742   of representative cultured fishes. Bull. Jap. Soc. Sci. Fish. 54 (1988) 1049-1054.

743 [32] J.G. Bell, J. McEvoy, D.R. Tocher, F. McGhee, P.J. Campbell, J.R. Sargent, Replacement of fish oil with
744   rapeseed oil in diets of Atlantic salmon (*Salmo salar*) affects tissue lipid compositions and hepatocyte fatty
745   acid metabolism. J. Nutr. 131 (2001) 1535–1543.

746 [33] AOAC, Official Methods of Analysis of the AOAC, Fifteenth. ed. AOAC International, Washington DC,
747   1990.

748 [34] V. Denstadli, A. Skrede, Å., Krogdahl, S. Sahlstrøm, T. Storebakken, Feed intake, growth, feed conversion,
749   digestibility, enzyme activities and intestinal structure in Atlantic salmon (*Salmo salar* L.) fed graded levels
750   of phytic acid. Aquaculture 15 (2006) 365–376.

751 [35] S. Helland, V. Denstadli, P.E. Witten, K. Hjelde, T. Storebakken, A. Skrede, T. Åsgård, G. Baeverfjord,
752   Hyper dense vertebrae and mineral content in Atlantic salmon (*Salmo salar* L.) fed diets with graded levels
753   of phytic acid. Aquaculture 261 (2006) 603–614.

754 [36] B.E. Torstensen, M. Espe, M. Sanden, I. Stubhaug, R. Waagbø, G.-I. Hemre, R. Fontanillas, U. Nordgarden,
755   E.M. Hevrøy, P. Olsvik, M.H.G. Berntssen, Novel production of Atlantic salmon (*Salmo salar*) protein
756   based on combined replacement of fish meal and fish oil with plant meal and vegetable oil blends.
757   Aquaculture 285 (2008) 193–200.

758 [37] G. Francis, H.P. Makkar, K. Becker, Antinutritional factors present in plant-derived alternate fish feed
759   ingredients and their effects in fish. Aquaculture 199 (2001) 197–227.

760 [38] B. Liaset, M. Espe, Nutritional composition of soluble and insoluble fractions obtained by enzymatic
761   hydrolysis of fish-raw materials. Process Biochem. 43 (2008) 42–48.

762 [39] P.A.J. Prabhu, J.W. Schrama, S.J. Kaushik, Quantifying dietary phosphorus requirement of fish – a meta-
763   analytic approach. Aquac. Nutr. 19 (2013) 233–249.

764 [40] P.A.J. Prabhu, J.W. Schrama, S.J. Kaushik, Mineral requirements of fish: a systematic review. Rev. Aquac.
765   6 (2014) 1–48.

766 [41] B.E. Torstensen, Nutrients not ingredients! *Fiskeribladet Fiskaren* (2014) Available online from 27/03/2015
767   at: http://nifes.no/en/nutrients-ingredients/.

768 [42] R. Waagbø, K. Sadnes, S. Espelid, O. Lie, Haematological and biochemical analyses of Atlantic salmon,
769   *Salmo salar* L., suffering from coldwater vibriosis ('Hitra disease'). J. Fish Dis. 11 (1988) 417–423.

770 [43] G.K. Iwama, Stress in Fish. Ann. N. Y. Acad. Sci. 851 (1998) 304–310.

771 [44] S. Nikoskelainen, J. Lehtinen, E.M. Lilius, Bacteriolytic activity of rainbow trout (*Oncorhynchus mykiss*)
772   complement. Dev. Comp. Immunol. 26 (2002) 797–804.

773 [45] V. Kiron, Fish immune system and its nutritional modulation for preventive health care. Anim. Feed Sci.
774   Technol. 173 (2012) 111–133.

775 [46] K.D. Thompson, M.F. Tatner, R.J. Henderson, Effects of dietary (n-3) and (n-6) polyunsaturated fatty acid
776   ratio on the immune response of Atlantic salmon, *Salmo salar* L. Aquac. Nutr. 2 (1996) 21–31.

777 [47] W.R. Beisel, Metabolic and nutritional consequences of infection, in: H.H. Draper (Ed.), Advances in
778   Nutritional Research. Plenum Press, New York, 1997, pp. 125–144.

779 [48] R.W. Wannemacher, Key role of various individual amino acids in host response to infection. Am. J. Clin.
780   Nutr. 30 (1977) 1269–1280.

781 [49] M.P. Bransden, C.G. Carter, B.F. Nowak, Effects of dietary protein source on growth, immune function,
782   blood chemistry and disease resistance of Atlantic salmon (*Salmo Salar* L.) parr. Anim. Sci. 73 (2001) 105
783   – 113.

784 [50] M. Farhangi, C.G. Carter, Growth, physiological and immunological responses of rainbow trout
785   (*Oncorhynchus mykiss*) to different dietary inclusion levels of dehulled lupin (*Lupinus angustifolius*).
786   Aquac. Res. 32 (2001) 329–340.

787 [51] W.B. van Muiswinkel, G.F. Wiegertjes, Immune responses after injection vaccination of fish. Dev. Biol.
788   Stand. 90 (1997) 55–57.

789 [52] A.K. Siwicki, M. Morand, K. Kazuñ, N. Keck, Application of anti-stress products in aquaculture: influence
790   of propiscin on the effectiveness of an anti-*Yersinia ruckerii* vaccine in rainbow trout *Oncorhynchus mykiss*
791   (Wal.). Arch. Polish Fish. 10 (2002) 143–152.

792 [53] G.O. Melingen, H.I. Wergeland, Serum protein and IgM profiles in connection with the smolting and
793   vaccination of out-of-season Atlantic salmon (*Salmo salar* L.). Aquaculture 188 (2000) 189–201.

794 [54] I.R. Bricknell, J.A. King, T.J. Bowden, A.E. Ellis, Duration of protective antibodies, and the correlation with
795   protection in Atlantic salmon (*Salmo salar* L.), following vaccination with an *Aeromonas salmonicida*
796   vaccine containing iron-regulated outer membrane proteins and secretory polysaccharide. Fish Shellfish
797   Immunol. 9 (1999) 139–151.

798 [55] K.R. Villumsen, I. Dalsgaard, L. Holten-Andersen, M.K. Raida, Potential role of specific antibodies as
799   important vaccine induced protective mechanism against *Aeromonas salmonicida* in rainbow trout. PLoS
800   One 7 (2012) e46733.

801 [56] S. Espelid, G.B. Løkken, K. Steiro, J. Bøgwald, Effects of cortisol and stress on the immune system in
802   Atlantic Salmon (*Salmo salar* L.). Fish Shellfish Immunol. 6 (1996) 95–110.

803 [57] B.O. Kvamme, K. Gadan, F. Finne-Fridell, L. Niklasson, H. Sundh, K. Sundell, G.L. Taranger, Ø. Evensen,
804   Modulation of innate immune responses in Atlantic salmon by chronic hypoxia-induced stress. Fish
805   Shellfish Immunol. 34 (2013) 55–65.

806 [58] J.I. Erdal, L.J. Reitan, Immune response and protective immunity after vaccination of Atlantic salmon (*Salmo
807   salar* L.) against furunculosis. Fish Shellfish Immunol. 2 (2) (1992) 99–108.

808 [59] V. Kiron, A. Gunji, N. Okamoto, S. Satoh, Y. Ikeda, T. Watanabe, Dietary nutrient dependent variations on
809   natural-killer activity of the leucocytes of rainbow trout. Fish Pathol. 28 (1993) 71–76.

810 [60] V. Kiron, H. Fukuda, T. Takeuchi, T. Watanabe, Essential fatty acid nutrition and defence mechanisms in
811   rainbow trout *Oncorhynchus mykiss*. Comp. Biochem. Physiol. Part A Physiol. 111 (1995) 361–367.

812 [61] D.P. Anderson, Immunostimulants, adjuvants, and vaccine carriers in fish: Applications to aquaculture.
813   Annu. Rev. Fish Dis. 2 (1992) 281–307.

814 [62] A.L. Gannam, R.M. Schrock, Immunostimulants in fish diets. J. Appl. Aquac. 9 (1999) 53–89.

815 [63] F. Geay, S. Ferraresso, J.L. Zambonino-Infante, L. Bargelloni, C. Quentel, M. Vandeputte, S. Kaushik, C.L.
816   Cahu, D. Mazurais, Effects of the total replacement of fish-based diet with plant-based diet on the hepatic
817   transcriptome of two European sea bass (*Dicentrarchus labrax*) half-sibfamilies showing different growth
818   rates with the plant-based diet. BMC Genomics 12 (2011) 522.

819 [64] M. Claire, H. Holland, J. D. Lambris, The cmplement system of teleosts Fish. Fish Shellfish Immunol. 6
820   (2002) 399–420.

821   [65] H. Boshra, J. Li, J.O. Sunyer, Recent advances on the complement system of teleost fish. Fish Shellfish
822   Immunol. 20 (2006) 239–62.

823   [66] B. Magnadottir, Innate immunity of fish (overview). Fish Shellfish Immunol. 20 (2006) 137–151.

824   [67] J.M. Daly, M. John M., J. Reynolds, R. K. Sigal, J. Shiou; M.D. Liberman, Effect of dietary protein and
825   amino acids on immune function. Crit. Care Med. 18 (1990) 2.
826
827   [68] P. Li, Y.-L. Yin, D. Li, S.W. Kim, G. Wu, Amino acids and immunity. Br. J. Nutr. 98 (2) (2007) 237-252.

828   [69] W.M. Rauw. Immune response from a resource allocation perspective. Front. Genetics 3 (267) (2012) 1-14.

829   [70] T.T. Poppe, E.O. Koppang, Side-Effects of Vaccination, in: R. Gudding, A. Lillehaug, Ø. Evensen (Eds.),
830   Fish Vaccination. John Wiley & Sons, Ltd, Chichester, UK, 2014, pp. 153-161.

831   [71] Aliphos, The role of Phosphorus for Salmonids. Talk. Feed Ingredients. Feed Ingredients news from Aliphos,
832   2012, pp. 1–6.

833   [72] C. Uribe, H. Folch, R. Enriquez, G. Moran, Innate and adaptive immunity in teleost fish: A review. Vet. Med.
834   (Praha). 56 (2011) 486–503.

835   [73] T.J. Bowden, Modulation of the immune system of fish by their environment. Fish Shellfish Immunol. 25
836   (2008) 373–383.

837   [74] A.M. Henken, A.J. Tigcehelaar, W.B. van Muiswinkel, Effects of feeding level on antibody production in
838   African catfish, Clarias gariepinus Burchell, after injection of Yersinia ruckerii O-antigen. J. Fish Dis. 11
839   (1988) 85-88.

840   [75] R.T. Lovell, Feed deprivation increases resistance of channel catfish to bacterial infection. Aquac. Asia Mag.
841   6 (1996) 65-67.

842   [76] M.F. Tatner, Natural changes in the immune system of fish. In: G.K. Iwama, T. Nakanishi (Eds), The Fish
843   Immune system, Academic Press San Diego, CA, USA, 1997, Vol. 15, pp. 255-287.

844

845

846

847

848

849

850

851

852

853

854

Figure Caption

856 **Figure 1.** Observed mortality curves in the quadruplicate tanks of the experimental dietary
857 groups of intra-peritoneally challenged against *A. salmonicida* Atlantic salmon parr (PBS-
858 injected) and cumulative mortality curves for the three dietary groups (PBS-injected).

859

**Figure 1.**

862 **Table 1.** Formulation and chemical composition of the experimental diets.

Feed composition ($\times kg^{-1}$)	SPC35	SPC58	SPC80	SPC35	SPC58	SPC80
		2mm			3mm	
Fishmeal [a] (g)	449.2	269.8	114.6	449.2	269.8	114.6
SPC [b] (g)	288.3	453.8	598.6	288.3	453.8	598.6
Tapioca [c] (g)	110.0	100.0	90.0	110.0	100.0	90.0
MonoCalcium phosphate [d] (g)	20.0	30.0	40.0	20.0	30.0	40.0
Vitamin and mineral premixes[e] (g)	4.0	4.0	4.0	4.0	4.0	4.0
Vitamin C 35% [e] (g)	1.0	1.0	1.0	1.0	1.0	1.0
Methionine [f] (g)	2.1	4.0	5.5	2.1	4.0	5.5
Lysine 78% [f] (g)	1.8	2.6	3.3	1.8	2.6	3.3
L-Threonine [f] (g)	0.6	0.8	1.0	0.6	0.8	1.0
Nobacithin Powder [g] (g)	10.0	10.0	10.0	10.0	10.0	10.0
Fish Oil [h](g)	113.0	124.0	132.0	113.0	124.0	132.0
Chemical composition ($\times kg^{-1}$)						
Dry matter (g)	959.7	944.1	923.0	923.2	936.1	922.5
In dry matter basis						
Energy (KJ)	222.4	218.9	216.3	223.8	218.8	217.1
Crude protein (g)	531.2	515.2	494.1	532.4	511.8	489.8
Crude fat (g)	182.4	170.6	162.0	177.7	165.4	162.1
Crude prt: Crude fat ratio	29.1	30.2	30.5	29.9	30.9	30.3
Ash (g)	95.5	92.5	89.0	96.1	91.0	87.6
Carbohydrate (g)	289.7	307.9	332.4	287.8	308.0	318.8
Crude fibre (g)	0.1	0.2	0.3	0.1	0.2	0.3
Phytic acid (g)	11.5	14.7	15.4	10.6	13.7	14.2
Phytic acid-bound P (g)	3.0	3.8	3.8	2.7	3.6	3.5
P (g)	16.0	16.1	15.0	15.7	16.1	15.4
Ca (g)	15.1	14.0	11.5	14.8	13.6	11.5
Ca: P ratio	0.9	0.9	0.8	0.9	0.8	0.7
Zn (mg)	295.3	295.3	266.5	280.6	285.9	267.6
Mg (g)	2.3	2.4	2.4	2.1	2.3	2.4
Mn (mg)	84.0	90.0	84.4	82.4	87.8	85.5

863 Abbreviations: SPC 35 - diet with 35% of dietary protein from soy protein concentrate (SPC);
864 SPC 58 - diet with 58% of dietary protein from SPC; SPC 80 - diet with 80% of dietary protein
865 from SPC.
866 * The concentrations of phytic acid and phytic acid-bound P were estimated using a Megazyme
867 Phytate/Total Phosphorus Assay kit (Megazyme, Ireland) following the protocols provided by
868 the company and were then corrected according to the total dietary P values estimated via
869 ICP/MS.
870 [a] Fishmeal (Egersund Sildoljefabrikk, Norway) with an apparent protein digestibility
871 coefficient (ADC protein) of 90.2 %
872 [b] SPC (*62 % crude protein) (Imcopa, Paraná, Brazil) with an apparent protein digestibility
873 coefficient (ADC protein) of 90.8 % (Anti-trypsins <3.0 mg $\times$ g^{-1}, Fibre <5.0 mg $\times$ g^{-1}, Lectins
874 < 0.1 µg $\times$ g^{-1}, Saponins = 0%, Glycinin < 3.0 µg $\times$ g^{-1}, β-conglycinin < 1.0 µg $\times$ g^{-1})
875 (compositional analyses performed by an authorised external laboratory hired by Imcopa)

876   [c] Tapioca (Hoff Norske Potetindustrier, Gjøvik, Norway)
877   [d] Monocalcium Phosphate (Normin AS, Hønefoss, Norway)
878   [e] Vitamin premix and Mineral premix (EWOS AS, Bergen, Norway)
879   [f] Amino acids (Evonik Degussa International AG, Hanau, Germany)
880   [g] Nobacithin: De-oiled lecithin powder (Noba Vital Lipids, Netherlands);
881   [h] Fish Oil (Egersund Sildoljefabrikk, Norway).
882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910 **Table 2.** Performance data of juvenile Atlantic salmon dietary groups

Growth and survival	SPC35	SPC58	SPC80
Average initial weight (g) (Day 0)	*9.3±0.06*	*9.3±0.16*	*9.3±0.12*
Average intermediate weight (g) (Day 92)	34.2±0.65[a]	32.7±0.56[b]	30.5±0.62[c]
Average Weight (Vac. Fish) (Day 92)	*34.8±4.45*	*32.6±0.94*	*30.2±0.95*
Average final weight (g) (Day 154) Vacc. fish	55.5±6.18[a]	52.6±2.16[ab]	47.4±1.12[b]
Average weight (PBS-inj. fish) (Day 92)	*35.2±1.29*	*33.6±1.02*	*30.6±1.56*
Average final weight (g) (Day 154) PBSinj. fish	59.9±3.10[a]	57.3±1.04[a]	49.5±2.94[b]
Weight gain (g×fish^{-1}×day^{-1}) (Days 0-92)	0.27±0.01[a]	0.25±0.01[a]	0.23±0.01[b]
Weight gain (g×fish^{-1}×day^{-1}) (Days 92-154) Vacc. fish	0.33±0.04[a]	0.32±0.02[ab]	0.28±0.01[b]
Weight gain (g×fish^{-1}×day^{-1}) (Days 92-154) PBSinj. fish	0.40±0.03[a]	0.38±0.02[a]	0.30±0.02[b]
SGR (Days 0-92)	1.50±0.03[a]	1.45±0.03[b]	1.38±0.02[c]
SGR (Days 92-154) Vacc. fish	0.88±0.07	0.90±0.04	0.85±0.02
SGR (Days 92-154) PBSinj. fish	1.00±0.03[a]	1.01±0.06[a]	0.91±0.02[b]
TGC (Days 0-92)	1.03±0.02[a]	0.98±0.02[b]	0.92±0.01[c]
TGC (Days 92-154) Vacc. fish	0.74±0.06	0.74±0.04	0.68±0.01
TGC (Days 92-154) PBSinj. fish	0.86±0.04[a]	0.85±0.05[a]	0.73±0.03[b]
Feed Intake (0-92)	0.22±0.01[a]	0.22±0.01[a]	0.21±0.00[b]
Feed Intake (Days 92-154) Vacc. fish	0.29±0.02	0.28±0.01	0.27±0.02
Feed Intake (Days 92-154) PBSinj. fish	0.38±0.02	0.38±0.01	0.38±0.01
FCR (0-92)	0.82±0.04[a]	0.85±0.03[ab]	0.89±0.01[b]
FCR (Days 92-154) Vacc. fish	0.87±0.06[a]	0.86±0.04[ab]	0.96±0.06[b]
FCR (Days 92-154) PBSinj. fish	0.96±0.03[a]	1.00±0.06[a]	1.24±0.09[b]
Mortalities (%)	0.00±0.00	0.00±0.00	0.01±0.01
Mortalities (%) (Days 92-154) Vacc. fish	0.01±0.01	0.01±0.01	0.01±0.01
Mortalities (%) (Days 92-154) PBSinj. fish	0.00±0.00	0.00±0.00	0.01±0.01

911 Abbreviations: SPC 35 - diet with 35% of dietary protein from soy protein concentrate (SPC);
912 SPC 58 - diet with 58% of dietary protein from SPC; SPC 80 - diet with 80% of dietary protein
913 from SPC.
914 Data for growth performance represent means ± SEM for 4 replicate tanks.

915   Significant differences among dietary groups at each timepoint are given with different
916   superscript letters within each row.
917   *Weight gain (WG) (g × fish^{-1} × day^{-1}) = (Final Biomass-Initial Biomass)/ (N × t)
918
919      $SGR = [(\ln W1 - \ln W0)/t] \times 100$
920      $TGC = [(\sqrt[3]{W1} - \sqrt[3]{W0})/(t \times T)] \times 1000$
921   Feed Intake (FI) (g × fish^{-1} × day^{-1}) = (W$_{fg}$ – W$_{fc}$)/ (N × t)
922      $FCR = (W_{fg} - W_{fc})/(W1 - W0)$
923   where: t = Number of days
924   T = Average water temperature in ° C
925   N = Number of fish
926            $W1$ = Average final weight (g)
927            $W0$ = Average initial weight (g)
928   W_{fg} = Weight of feed given (g)
929   W_{fc} = Cumulative weight of feed collected at the end of each feeding (g)
930

Table 3. Immune responses of the dietary groups of salmon parr at different timepoints/states

Pre vaccination	SPC35	SPC58	SPC80
Lysozyme act. (units $\times$ min$^{-1}\times$ ml^{-1} of serum)	701.9±48.7	656.3±60.0	653.1±48.8
Alternative complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	90.1±14.5	78.9±11.0	99.4±17.9
Classical complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	436.9±46.3[a]	260.9±19.3[b]	314.0±50.0[ab]
Total complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	527.0±49.8[a]	339.7±18.2[b]	413.4±53.5[ab]
HKMs resp. burst (NBT) (OD for 10^5 nuclei)	0.5±0.1	0.7±0.1	0.6±0.1
Stimulated HKMs resp. burst (OD for 10^5 nuclei)	0.6±0.4	0.8±0.1	0.7±±0.2
Phagocytic Index	1.8±0.0	1.9±0.3	1.4±0.2
Phagocytosis (% of HKMs performing phagocytosis)	49.1±4.2	52.9±9.9	46.3±4.6
Total serum protein (mg $\times$ ml^{-1} of serum)	33.1±2.9	30.0±3.2	30.9±2.2
Serum glucose (mmol $\times$ ml^{-1} of serum)	6.8±0.3	6.5±0.2	6.3±0.3
Total serum IgM (mg $\times$ ml^{-1} of serum)	2.8±1.6	1.7±0.5	1.2±0.3
2 days post vaccination			
Lysozyme act. (units $\times$ min$^{-1}\times$ ml^{-1} of serum)	728.1±30.9	775.6±56.9	735.0±16.7
Alternative complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	95.7±8.1[a]	52.3±15.4[b]	52.0±8.6[b]
Classical complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	240.2±52.7	260.7±59.6	328.1±74.9
Total complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	335.9±52.9	313.0±63.1	380.2±74.1
HKMs resp. burst (NBT) (OD for 10^5 nuclei)	0.7±0.1	0.8±0.1	0.8±0.1
Stimulated HKMs resp. burst (OD for 10^5 nuclei)	1.1±0.1	1.1±0.1	1.3±0.2
Phagocytic Index	5.9±0.3	6.5±0.4	7.0±0.9
Phagocytosis (% of HKMs performing phagocytosis)	76.8±3.5	75.4±2.6	79.4±3.1
Total serum protein (mg $\times$ ml^{-1} of serum)	24.4±5.8	26.6±3.5	21.3±2.2
Serum glucose (mmol $\times$ ml^{-1} of serum)	9.1±0.8	11.1±1.7	9.7±0.7
Total serum IgM (mg $\times$ ml^{-1} of serum)	0.6±0.3	1.2±0.4	0.7±0.3
2 days post PBS-injection			
Lysozyme act. (units $\times$ min$^{-1}\times$ ml^{-1} of serum)	_	_	_
Alternative complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	_	_	_
Classical complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	_	_	_
Total complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	_	_	_
HKMs resp. burst (NBT) (OD for 10^5 nuclei)	0.6±0.1	0.8±0.1	0.8±0.1
Stimulated HKMs resp. burst (OD for 10^5 nuclei)	1.0±0.2	1.1±0.1	1.0±0.2
Phagocytic Index	4.8±0.4	4.5±0.5	5.3±0.3
Phagocytosis (% of HKMs performing phagocytosis)	68.3±1.6	70.8±1.9	72.3±2.1
Total serum protein (mg $\times$ ml^{-1} of serum)	_	_	_
Serum glucose (mmol $\times$ ml^{-1} of serum)	_	_	_
Total serum IgM (mg $\times$ ml^{-1} of serum)	_	_	_
62 days post vaccination			
Lysozyme act. (units $\times$ min$^{-1}\times$ ml^{-1} of serum)	867.5±30.2	810.0±113.8	811.9±77.5
Alternative complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	82.3±8.5[a]	69.3±11.5[ab]	47.4±17.5[b]
Classical complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	303.9±35.1	334.2±77.8	513.8±107.8
Total complement act. (units H$_{50}$ $\times$ ml^{-1} of serum)	386.2±32.1	403.5±83.3	561.2±107.3
HKMs resp. burst (NBT) (OD for 10^5 nuclei)	0.5±0.1	0.3±0.1	0.3±0.1

Stimulated HKMs resp. burst (OD for 10^5 nuclei)	0.7±0.2	0.4±0.1	0.5±0.1
Phagocytic Index	1.0±0.2	1.1±0.1	0.9±0.1
Phagocytosis (% of HKMs performing phagocytosis)	38.6±5.7	44.9±2.8	36.9±3.6
Total serum protein (mg × ml^{-1} of serum)	31.0±3.0	29.5±2.1	28.0±2.5
Serum glucose (mmol × ml^{-1} of serum)	5.5±0.3	5.4±0.3	5.4±0.2
Total serum IgM (mg × ml^{-1} of serum)	9.0±1.8	8.5±1.9	5.1±0.6
Specific IgM (serum titers)	0.5±0.1	0.3±0.1	0.3±0.1
62 days post PBS-injection			
Lysozyme act. (units × min^{-1}× ml^{-1} of serum)	702.5±49.6	707.5±16.8	711.9±59.6
Alternative complement act. (units H_{50} × ml^{-1} of serum)	209.8±13.6	189.2±34.5	130.6±12.0
Classical complement act. (units H_{50} × ml^{-1} of serum)	383.6±56.7	379.2±44.1	402.0±91.0
Total complement act. (units H_{50} × ml^{-1} of serum)	593.4±59.8	568.3±50.0	532.6±94.2
HKMs resp. burst (NBT) (OD for 10^5 nuclei)	2.5±0.6	2.1±0.3	2.2±0.5
Stimulated HKMs resp. burst (OD for 10^5 nuclei)	4.3±1.4	3.7±0.7	4.5±1.5
Phagocytic Index	0.3±0.1[a]	0.8±0.1[b]	0.8±0.2[ab]
Phagocytosis (% of HKMs performing phagocytosis)	20.6±5.2[a]	39.6±3.2[b]	37.5±6.1[ab]
Total serum protein (mg × ml^{-1} of serum)	61.6±2.3	60.3±6.7	59.3±3.2
Serum glucose (mmol × ml^{-1} of serum)	6.6±0.4	6.1±0.2	6.4±0.3
Total serum IgM (mg × ml^{-1} of serum)	0.8±0.3	0.9±0.2	1.3±0.4

932 Abbreviations: SPC 35 - diet with 35% of dietary protein from soy protein concentrate (SPC);
933 SPC 58 - diet with 58% of dietary protein from SPC; SPC 80 - diet with 80% of dietary protein
934 from SPC.
935 Data for growth performance represent means ± SEM for 4 replicate tanks.
936 Significant differences among dietary groups at each timepoint are given with different
937 superscript letters within each row.
938

939